Pfizer Rumoured To Be Reducing 5th of Primary Care Workforce
Pfizer is believed to be cutting approximately 600 jobs this month from their primary care business.
The organisation’s primary care sector have a variety of key drugs, including pain killer Lyrica, ED drug Viagra and arthritis drug Celebrex.
“As part of our strategy to allocate our resources, investments and people to the areas that best serve our patients and customers, we continually evaluate how we can be more efficient and effective,” Mackay Jimeson, a Pfizer spokesman, informed Bloomberg, who spoke to the individual familiar with the matter surrounding the rumour.
“As a result, we are making changes in some segments of our field force to better match the future needs of the business,” Jimeson added.
Before the dismissals, Pfizer had roughly 3,000 primary care salespeople and managers, according to PharmaForce International, which tracks pharmaceutical sales forces and provides market intelligence.
This announcement arises after Pfizer lost patent protection for their largest selling drug Lipitor in all key markets earlier in the year, drastically reducing the once $12 billion in peak annual sales the drug brought in.
The company have already taken strides to counteract the revenue by making reductions to some of their R&D centres, most notably their European research HQ in Sandwich, UK, which has been radically downsized in the past 18 months.